GSK, Teva Pick Up Steam In Lamictal Pay-For-Delay Cert Bid
GlaxoSmithKline and Teva Pharmaceutical Industries Ltd. are picking up more allies in their push to have the U.S. Supreme Court reverse a Third Circuit ruling forcing them to face antitrust claims...To view the full article, register now.
Already a subscriber? Click here to view full article